Cancer Biology

Cancer is not one disease but more than two hundred, unified by a single underlying principle: cells that have escaped the molecular controls governing when they grow, when they divide, and when they die. That escape is genetic — acquired mutations and epigenetic changes that progressively rewire a cell’s internal signalling circuitry, converting normal growth-regulated behaviour into the relentless proliferation, invasion, and dissemination that define malignancy. Understanding cancer at its molecular roots — in the proto-oncogenes that encode growth-promoting signals, the tumour suppressor genes that encode growth-restraining brakes, and the cell cycle machinery that executes the division program — is not merely academic. It is the foundation on which every targeted cancer therapy, every prognostic biomarker, every cancer screening programme, and every inherited cancer risk assessment is built.

Cancer as a Genetic Disease — Somatic Mutations and Clonal Evolution

Cancer is fundamentally a genetic disease of somatic cells. Unlike inherited genetic diseases caused by germline mutations present in every cell of the body from conception, most cancers arise from somatic mutations — alterations in the DNA of a single normal cell that confer on it and its descendants a selective growth advantage over surrounding cells. This altered cell proliferates, accumulates additional mutations under the selective pressure of the tumour microenvironment and immune surveillance, and over years to decades produces the genetically heterogeneous tumour mass characteristic of advanced malignancy. The process is clonal evolution — a somatic Darwinian process in which cells with mutations conferring growth, survival, or evasion advantages are selected and expand.

The genetic changes that drive cancer fall into two broad categories defined by their effect on the affected gene: gain-of-function mutations in proto-oncogenes that activate growth-promoting signals constitutively, and loss-of-function mutations in tumour suppressor genes that remove growth-restraining controls. A third category — mutations in DNA repair and genome maintenance genes — does not directly drive proliferation but dramatically accelerates the accumulation of mutations in proto-oncogenes and tumour suppressors, acting as a catalyst for carcinogenesis. According to the National Cancer Institute’s cancer biology resource, these three gene classes — proto-oncogenes, tumour suppressors, and DNA repair genes — are the core molecular targets whose alteration drives cancer progression across virtually all cancer types.

Multistep Carcinogenesis — the Progressive Accumulation of Genetic Damage

No single mutation transforms a normal cell into a fully malignant cancer cell. The development of cancer requires the sequential accumulation of multiple genetic and epigenetic alterations — typically between three and ten driver mutations in most common solid tumours — that progressively dismantle the multiple redundant control systems that normally prevent unrestricted proliferation. This multistep model was first clearly articulated through the study of colorectal cancer progression, where the adenoma-carcinoma sequence provides a morphologically trackable series of stages that correlate precisely with the accumulation of specific genetic alterations.

Proto-Oncogenes — Normal Cellular Genes Encoding Growth Signals

Proto-oncogenes encode proteins that are essential for normal cell growth, proliferation, differentiation, and survival. Their products include growth factors (PDGF, EGF, FGF), growth factor receptors with intrinsic tyrosine kinase activity (EGFR/ErbB1, HER2/ErbB2, PDGFR, FGFR, KIT, RET, MET), signal transducers (RAS family GTPases, RAF serine-threonine kinase, PI3K catalytic subunit, ABL tyrosine kinase, SRC non-receptor tyrosine kinase), and nuclear transcription factors (MYC, MYCN, FOS, JUN, REL/NF-κB). Under normal physiological conditions, proto-oncogene activation is transient, ligand-dependent, and tightly regulated by negative feedback mechanisms — growth factor receptor activation is extinguished within minutes by receptor endocytosis, GTPase-activating proteins (GAPs) that hydrolyse active RAS-GTP to inactive RAS-GDP, and phosphatase activity reversing kinase activations.

Oncogene Activation Mechanisms — Four Routes from Proto-Oncogene to Oncogene

Key Oncogenes — the Molecular Architects of Malignant Growth

While hundreds of oncogenes have been identified, a relatively small number of signalling proteins appear as oncogenic drivers across multiple cancer types — reflecting their central position in growth control circuitry and the particular vulnerability of their regulatory mechanisms to gain-of-function alteration.

Tumour Suppressor Genes — the Brakes on Uncontrolled Growth

Tumour suppressor genes (TSGs) are the molecular counterweights to oncogenes — genes whose normal function restrains cell proliferation, enforces apoptosis when appropriate, maintains genomic integrity, or promotes terminal differentiation. While oncogene mutations are dominant (one mutant allele drives the phenotype), TSG mutations are typically recessive — both alleles must be inactivated to abolish function (with some important exceptions involving haploinsufficiency and dominant-negative effects). The inactivating events that compromise TSG function are mechanistically diverse: point mutations introducing stop codons or splice site alterations; deletions removing part or all of the gene; loss of heterozygosity (LOH) removing the remaining wild-type allele; and epigenetic silencing through promoter CpG island hypermethylation (transcriptional silencing without DNA sequence change). The spectrum of TSG inactivation mechanisms is clinically important because epigenetic silencing — unlike point mutations or deletions — is potentially reversible with hypomethylating agents or HDAC inhibitors, and because identifying silencing vs deletion has implications for diagnostic testing strategies.

The Two-Hit Hypothesis — Knudson’s Statistical Insight

TP53 — the Guardian of the Genome

The tumour suppressor protein p53 — encoded by TP53 on chromosome 17p13.1 — occupies a singular position in cancer biology: it is the most frequently mutated gene in human cancer (approximately 50% of all malignancies), the central integrator of the cellular stress response, and the molecular checkpoint that determines whether a cell with DNA damage undergoes repair and survival, cell cycle arrest, or apoptotic elimination. Fittingly, it was named the “guardian of the genome” by David Lane in 1992 — a metaphor that has proven extraordinarily apt in the decades of mechanistic dissection that followed.

TP53 mutations in cancer are overwhelmingly missense mutations (rather than nonsense, frameshift, or splice-site mutations) clustering in five “hotspot” codons in the DNA-binding domain: R175H, G245S, R248W, R248Q, R249S, and R273H/C — residues that either contact DNA directly or maintain the structural integrity of the DNA-binding surface. This unusual distribution of missense mutations (rather than protein-truncating mutations) reflects two biological properties: first, a dominant-negative effect — mutant p53 protein forms tetramers with wild-type p53 monomers (p53 functions as a tetramer), and a single mutant subunit can impair the entire tetramer’s DNA binding capacity, explaining why p53 behaves like a dominant mutation in many contexts despite being a tumour suppressor; second, gain-of-function activities — hotspot mutant p53 proteins interact with and activate other transcription factors (MYC, YAP, NF-Y) that drive invasion, metastasis, and drug resistance programmes.

The Retinoblastoma Protein — Gatekeeper of the G1/S Restriction Point

The retinoblastoma protein (Rb, encoded by RB1 at chromosome 13q14) is the archetypal tumour suppressor — the first to be cloned and the one that most clearly embodies both the two-hit model and the concept of a cell cycle gatekeeper. Its molecular function is deceptively focused: Rb controls a single but absolutely critical decision point in the cell cycle — the restriction point in late G1, after which cells commit to division regardless of extracellular growth signals. The restriction point is the molecular equivalent of passing the point of no return, and Rb is the molecular gatekeeper standing at that threshold.

QUIESCENT / EARLY G1 — Rb active (hypophosphorylated)
  Rb binds E2F transcription factors (E2F1–E2F3) at their transactivation domain
  Rb–E2F complex recruits HDAC and polycomb repressor complexes → chromatin compaction
  S phase genes SILENCED: cyclin E, cyclin A, DHFR, thymidine kinase, MCM helicases
  Cell cannot enter S phase regardless of growth factor availability

MID-G1 — Growth factor signalling initiates Rb phosphorylation
  Growth factors → RTK → RAS → RAF → MEK → ERK → cyclin D1 transcription
  Cyclin D1–CDK4/6 complex → phosphorylates Rb at Ser780, Ser795, Ser807/811
  Partial E2F release → cyclin E transcription begins
  CDK4/6 inhibited by p16/INK4a, p15/INK4b (RAS-independent TSG activity)

LATE G1 / RESTRICTION POINT — Rb hyperphosphorylated → inactivated
  Cyclin E–CDK2 → hyper-phosphorylates Rb (>12 residues) → complete E2F release
  Free E2F activates S phase gene battery → cell enters S phase
  Rb phosphorylation maintained through G2/M; dephosphorylated at mitotic exit by PP1
  Beyond restriction point: cell divides regardless of growth factor withdrawal

CANCER — Rb pathway inactivated by multiple mechanisms
  RB1 deletion/mutation (retinoblastoma, SCLC, osteosarcoma, TNBC)
  HPV E7 oncoprotein binds and degrades Rb (cervical carcinogenesis)
  Cyclin D1 amplification → excess CDK4/6 activity (breast, HNSCC, oesophageal)
  CDK4 amplification or V158D activating mutation (melanoma, liposarcoma)
  p16/INK4a deletion (CDKN2A, 9p21) → unrestrained CDK4/6 (~50% of all cancers)
  Result: Rb constitutively hyperphosphorylated → permanent E2F activation → unrestricted proliferation

THERAPEUTIC EXPLOITATION
  CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) → block Rb phosphorylation
  Effective in HR+/HER2− breast cancer with intact Rb → restore functional Rb activity
  Loss of Rb → primary resistance to CDK4/6 inhibitors (predictive biomarker)

Key Tumour Suppressor Genes Beyond p53 and Rb

While p53 and Rb represent the paradigm tumour suppressors, a large number of additional TSGs play critical roles across specific cancer types — each controlling a distinct aspect of cell growth, genome maintenance, signalling regulation, or cell fate determination. Their patterns of inactivation, the pathways they regulate, and the hereditary syndromes associated with their germline mutation collectively provide a detailed molecular map of cancer predisposition.

The Cell Cycle — Ordered Phases of Growth and Division

The cell cycle is the sequence of molecular events that drive a cell from its post-mitotic state through DNA replication to the production of two identical daughter cells. This tightly ordered process must be controlled with extraordinary fidelity — errors in replication, chromosome segregation, or cell division produce daughter cells with abnormal genomes that contribute to cancer. The cell cycle is not merely a biological timer but a decision-making machine: at each phase transition, the cell integrates information about its own readiness, extracellular nutrient and growth signal availability, and the integrity of its DNA, before committing to the next phase.

Cyclin-CDK Complexes and CDK Inhibitors — the Molecular Engine of Cell Cycle Progression

Cell cycle progression is driven by cyclin-dependent kinases (CDKs) — serine-threonine kinases that phosphorylate substrate proteins to promote phase transitions. CDKs require two things for activity: binding to a cyclin regulatory subunit (whose levels oscillate through the cycle, providing temporal control) and phosphorylation of an activating residue in the CDK activation loop (by CDK-activating kinase, CAK). Additional control layers include inhibitory phosphorylation (by Wee1 kinase on CDK1-Tyr15, removed by CDC25 phosphatase at mitotic entry) and binding of CDK inhibitor proteins (CKIs). The oscillation of cyclin levels — rising and falling in a defined temporal sequence — creates the unidirectional drive of the cell cycle. Cyclins are named for their oscillating levels (Latin: cyclus = cycle), first characterised by Timothy Hunt, whose work contributed to the 2001 Nobel Prize in Physiology or Medicine shared with Leland Hartwell and Paul Nurse.

DNA Damage Checkpoints — Surveillance Mechanisms Cancer Must Overcome

Cell cycle checkpoints are quality-control mechanisms that halt cell cycle progression when problems — DNA damage, incomplete replication, or misaligned chromosomes — are detected, providing time for repair before the defect is propagated to daughter cells. Cancer cells must overcome checkpoint function to proliferate despite the DNA damage and genomic instability that accumulate during malignant transformation. Checkpoint genes are therefore frequent targets of mutation or inactivation in cancer — most prominently TP53 (the critical G1/S checkpoint effector) but also ATM, ATR, CHK1, CHK2, BRCA1, and others. DNA damage checkpoint biology is also the molecular basis for the efficacy of many cancer therapies: radiation and DNA-damaging chemotherapy work by creating DNA lesions; their selectivity for cancer cells depends partly on checkpoint defects that force cancer cells to divide despite damage, whereas normal cells arrest and survive.

Apoptosis Dysregulation — How Cancer Cells Survive When They Should Die

Apoptosis — programmed cell death — is not merely a mechanism for eliminating cells with irreparably damaged DNA. It is a constant threat to cancer cells, which accumulate DNA damage, experience oncogene-induced replication stress, face nutrient and oxygen deprivation in poorly vascularised tumour regions, and are targeted by cytotoxic immune cells and cancer therapies. The ability to resist apoptotic signals is therefore an essential acquired capability during malignant transformation — one of the hallmarks of cancer. Understanding apoptosis dysregulation explains both why cancers develop and why they resist treatment.

Epigenetic Alterations in Cancer — Heritable Changes Without DNA Sequence Change

Cancer is increasingly understood as a disease of both genetic and epigenetic disruption. Epigenetic alterations — changes in gene expression that are heritable through cell divisions but do not involve alterations in the DNA nucleotide sequence — are present in virtually every cancer type, often affecting as many genes as somatic mutations. They include DNA methylation changes, histone modification alterations, chromatin remodelling defects, and non-coding RNA dysregulation. Unlike genetic mutations (permanent and structurally irreversible), epigenetic changes are chemically reversible — an important therapeutic consideration.

The Hallmarks of Cancer — a Functional Framework for Malignancy

In their landmark 2000 review in Cell, Robert Weinberg and Douglas Hanahan articulated six acquired functional capabilities shared by virtually all human cancers — the “hallmarks of cancer.” Extended in 2011 to include genome instability and tumour-promoting inflammation as enabling characteristics, and further updated in 2022 to add deregulated cellular energetics (Warburg effect), immune evasion, cellular plasticity, and senescent cells, the hallmarks framework provides the most influential organising principle in contemporary cancer biology. According to the NCI SEER cancer biology resource, understanding these functional capabilities — and the molecular mechanisms that enable each one — is foundational to all cancer biology coursework and clinical oncology.

Hereditary Cancer Syndromes — When the First Hit is Inherited

Hereditary cancer syndromes account for approximately 5–10% of all cancers — defined by germline mutations in TSGs or DNA repair genes that dramatically increase lifetime cancer risk in mutation carriers and their first-degree relatives. Identifying hereditary cancer enables cascade genetic testing, intensive surveillance (earlier and more frequent screening), risk-reducing interventions (prophylactic surgery, chemoprevention), and targeted therapeutic selection. The WHO cancer fact sheet highlights that recognising inherited risk is a critical component of cancer prevention strategy at both individual and population levels, as noted in their comprehensive cancer overview.

Targeted Therapies — Translating Cancer Biology into Precision Medicine

The molecular deconstruction of cancer over the past four decades — identifying driver oncogene mutations, tumour suppressor inactivation patterns, signalling pathway dependencies, and genome maintenance defects — has produced a revolution in cancer treatment. Targeted therapies exploit specific molecular vulnerabilities of cancer cells, offering the potential for greater efficacy and selectivity than conventional cytotoxic chemotherapy. The success of targeted therapy is proportional to the depth of molecular knowledge underpinning it: the most successful agents are those directed at constitutively active oncoproteins that tumour cells are “addicted to” — a state termed oncogene addiction — where cell survival depends so completely on the mutant signalling protein that its inhibition produces catastrophic cellular dysfunction.

Cancer Driver Genes — a Comparative Reference Table

Frequently Asked Questions About Cancer Biology